Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2018 / Articles / Mar / Pharma Logistics: Up in the Air or in Deep Water?
Manufacture Business Practice Technology and Equipment Trends & Forecasts Facilities & Equipment Technology & Manufacturing

Pharma Logistics: Up in the Air or in Deep Water?

Tens of billions of dollars’ worth of (bio)pharmaceuticals are scrapped every year because of logistical hitches. What can be done to improve the situation? And which mode of transport – air or sea – should companies choose?

By James Strachan 03/15/2018 1 min read

Share

What could be simpler than moving products from point A to point B? A great deal, as it turns out – especially when your product is a sensitive chemical compound or biological. Shippers from all sectors have to deal with warehousing, transportation, customs clearance and regulatory compliance as they transport their goods across the world (easier said than done). But pharma companies also have to maintain a strict cold chain, where temperature excursions can ruin millions of dollars’ worth of drug – not to mention the potential impact on patients.

A staggering $35 billion worth of pharma products are scrapped every year (see our infographic: What a Waste), and 30 percent of those losses are attributable to logistics issues alone. During the journey from point A to point B, there are numerous hand-offs and opportunities for things to go wrong. In this feature, you’ll hear about pallets being left for days in the baking Dubai heat, communication mishaps, and unexpected bankruptcies... Given the challenges posed by the logistics process, choosing the right method of transport is crucial. There are advantages and disadvantages to both air and sea freight: with sea generally saving on cost, and air being a quicker option that is more prone to temperature excursions. Recently, analysts have suggested that cost pressures and reliability issues have led pharma away from airfreight, which is instead taking to the seas. But as the industry shifts towards complex biologics and personalized therapies, will the trend continue? And what impact will new cold chain technologies and data monitoring systems have? Much has changed for the logistics industry over the past half a century, with pharma supply chains becoming increasingly international. And as emerging markets continue to develop regulatory infrastructure – further globalizing pharma supply chains – predicting the dominant mode of travel is no easy feat. Here, we speak with experts from within the logistics industry – from both sides of the air versus sea debate – to assess where pharma’s future lies.

Pharma Logistics 101: Up, Up and Away? Is the Tide Turning? Need for Speed Logistical Nightmares Air or Sea: the Verdict Compliance and Collaboration

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

About the Author(s)

James Strachan

Over the course of my Biomedical Sciences degree it dawned on me that my goal of becoming a scientist didn’t quite mesh with my lack of affinity for lab work. Thinking on my decision to pursue biology rather than English at age 15 – despite an aptitude for the latter – I realized that science writing was a way to combine what I loved with what I was good at. From there I set out to gather as much freelancing experience as I could, spending 2 years developing scientific content for International Innovation, before completing an MSc in Science Communication. After gaining invaluable experience in supporting the communications efforts of CERN and IN-PART, I joined Texere – where I am focused on producing consistently engaging, cutting-edge and innovative content for our specialist audiences around the world.

More Articles by James Strachan

False

Advertisement

Recommended

False

Related Content

What Trump’s Latest Moves Mean for the Industry
Business Practice Standards & Regulation Trends & Forecasts Bioprocessing - Upstream & Downstream
What Trump’s Latest Moves Mean for the Industry

May 27, 2025

6 min read

Audrey Greenberg’s latest insight on US-based manufacturing, Trump’s “Administration for A Healthy America”, and an ever-shifting regulatory environment.

Big Bad Pharma?
Business Practice Trends & Forecasts
Big Bad Pharma?

December 1, 2014

0 min read

The Ebola media frenzy has reminded the public how selfish our industry is. But, somehow, that doesn’t sound quite right...

Access All Areas
Business Practice Trends & Forecasts
Access All Areas

December 1, 2014

0 min read

The 2014 Access to Medicine index shows progress – but companies remain “conservative”

Care to ‘Patent Dance’?
Business Practice Trends & Forecasts
Care to ‘Patent Dance’?

December 1, 2014

0 min read

Amgen accuses Sandoz of snubbing its advances in a complex biosimilar dispute

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.